Navigation Links
CORRECTION: Viral Genetics Pursues Promising New Therapy for Lyme Disease With Grant from Time for Lyme, Inc.
Date:5/20/2009

SAN MARINO, Calif., May 20 /PRNewswire-FirstCall/ -- On April 16, 2009 and March 18, 2009, biotechnology firm Viral Genetics, Inc. (Pink Sheets: VRAL) announced "that the company is pursing a promising new therapy for Lyme Disease with funding from Time for Lyme, Inc., and the Turn Corner Foundation." This correction is to clarify that those grants were not made to Viral Genetics but were made directly to the University of Colorado where Dr. M. Karen Newell is a tenured professor. The University then applied the funds to promising research into a treatment for Lyme Disease that is being conducted by Dr. M. Karen Newell and her research group at the University of Colorado. Any inference in the press releases that the grants were made directly to Viral Genetics rather than the university is incorrect.

Viral Genetics has certain exclusive licenses and options from the University of Colorado under previously filed patent rights, the work by Dr. Karen. Viral Genetics' license with the University is in return for certain obligations and fees.

Viral Genetics, Inc. is a biotechnology company that discovers and develops immune-based therapies for HIV, AIDS and other autoimmune diseases using its thymus nuclear protein compound (TNP). The company recently entered into an exclusive license agreement with the University of Colorado and V-Clip Pharmaceuticals (a subsidiary of the company) to license technology that appears to explain TNP and provide a means to optimize therapies based on TNP for future clinical trials. For more information, visit www.viralgenetics.com.

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports filed with the SEC and after March 25, 2009, filed on the pink sheets web site. VGV-1 is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of VGV-1 in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of VGV-1 in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.

    Viral Genetics
    Haig Keledjian, 626-334-5310


'/>"/>
SOURCE Viral Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Correction: Lawrence County Raw Milk Dairy Tests Negative for Campylobacter; Raw Milk Sales Resumed
2. Correction: Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of Inverness Medical Innovations, Inc.
3. Correction: Evalve Announces CE Mark Approval of the Worlds First Percutaneous Valve Repair System
4. Correction: Therapist to Young Hollywood Says Male Stars in Psychological Trouble Get a Media Pass as Compared to Female Stars
5. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
6. National Viral Hepatitis Roundtable Observes World Hepatitis Day and Calls for Increased Federal Action
7. National Viral Hepatitis Roundtable Observes World Hepatitis Day and Calls for Increased Federal Action
8. Sales of Antiretroviral Agents Will Drive Substantial Six Percent Annual Growth in the HIV Drug Market Through 2013
9. World Health Assembly Forced to Postpone Decision on Viral Hepatitis
10. Viral Infection Might Trigger High Blood Pressure
11. Veterinarians at high risk for viral, bacterial infections from animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
Breaking Medicine Technology: